ASH 2011 lymphoma abstracts

1565 Early Assessment of Minimal Residual Disease (MRD) by Qualitative PCR for NPM-ALK Identifies Patients At Very High Risk of Relapse in Anaplastic Large Cell Lymphoma

1566 Mesenchymal Stromal Cells Orchestrate Follicular Lymphoma Cell Niche Through the CCL2-Dependent Recruitment and Polarization of Monocytes

1567 Hairy Cell Leukaemia Displaying Multiple Surface Immunoglobulin Isotypes Reveal a Functional B-Cell Receptor In Which Isotype Roles Differ

1568 Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

1569 c-MYC Drives PBK Expression in High-Grade Malignant Lymphomas Through E2F1

1570 Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression

1571 Rituximab Activation of AKT and HIF Pathways Is Dependent on Membrane Lipid Raft Cholesterol Levels in Lymphoma Cells

1572 Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience

1573 Distinct Human and Viral Interleukin-6 Profiles and Other Viral and Immunologic Abnormalities In KSHV-Associated Multicentric Castleman Disease: Relationship with Disease Activity and Individual Disease Manifestations

1574 Primary Intraocular Lymphomas Display A Remarkably Biased Immunoglobulin Heavy Chain Gene Repertoire and Precisely Targeted Somatic Hypermutation Suggesting Antigenic Selection of the Neoplastic Cells

1575 Serum Soluble Tumor Necrosis Factor Recepter 2 Levels Is Associated with the Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Regimen

1576 Reduced Specificity and Positive Predictive Value of Surveillance FDG-PET/CT for Diffuse Large Cell B Cell Lymphoma in the Rituximab Era

1577 Follicular Lymphoma with Diffuse Large B-Cell Component At Initial Diagnosis Appears to Be Associated with a Loss of BCL2 Translocation and Inferior Progression Free Survival

1578 Impact of Occult Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

1579 Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Overall Survival Regardless of Choice of Therapy Type or Observation

1580 Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment – a Single Institution Experience

1581 Serum Soluble LR11 As a Novel Biomarker for B Cell Lymphoma

1582 A Prognostic Index for Acute and Lymphoma Type Adult T-Cell Leukemia/Lymphoma

1583Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System

1584 Burkitt Lymphoma Specific Zinc Finger Protein ZNF385B Is Involved in Regulation of B Cell Apoptosis

1585Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

1586 TGF-β Is Selectively Expressed on Lymphoma B Cells and Regulates the Differentiation of Intratumoral T Cells in B-Cell Non-Hodgkin Lymphoma (NHL)

1587 Genomic Pathways and Potential Therapeutic Targets in Pediatric Burkitt Lymphoma (PBL): A Children’s Oncology Group Report

1588 Innmune-Related Risk Factors for Non-Hodgkin Lymphoma in Twins

1589 HIV-Associated Plasmablastic Lymphoma: A Multi-Institutional Study

1590 B Cell Lymphoma In Association with Multiple Myeloma: Analysis of the Biologic Relationship

1591 Elevated Monoclonal Free Light Chains Are a Serum Marker of ABC Type Diffuse Large B-Cell Lymphoma

1592 Prognostic Impact of Clinical and Tumor Associated Variables in a Population-Based Cohort of Mantle Cell Lymphomas in the Stockholm Region Between 1998-2010

1593 The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years

1594 Prognositc Inpact of Tumor-Infiltrating Cells Especially CD163 Positive Macrophage in DLBCL Treated with R-CHOP

1595 Baseline Quality of Life Assessed with the EORTC QLQ-C30 Predicts the Treatment Outcome of Patients with Diffuse Large B-Cell Lymphoma: Results of a Prospective Cohort Study

1596 Lymphoproliferative Disorder and Acquired C1-INH Deficiency. A Case Series of 48 Patients

1597 Usefulness of Positron Emission Tomography Using 18F-FDG Performed At Diagnosis and During Initial Chemotherapy for Imaging Primary Central Nervous System Lymphoma: A 24 Immunocompetent patient’s Study

1598 Clinical Significance of Serum Concentration of L-Kynurenine for T-Cell Lymphoma Treated with CHOP

1599 Herpes Zoster Is Associated with An Increased Risk of Subsequent Lymphoid Malignancies — A Population-Based Matched-Control Study in Taiwan

1600 Correlation of Fc Gamma RIIA Polymorphisms with EBV-Positivity and LMP1 Expression in Patients with Low Grade B-Cell Lymphomas

1601 High Rate of Initial Treatment Failure in Patients with Primary Mediastinal B-Cell Lymphoma Treated with R-CHOP

1602 Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

1603 Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496

1604 Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.

1605 CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

1606 Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2-3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis

1607 Associations of Methylene Tetrahydrofolate Reductase Polymorphism and Methotrexate-Related Toxicities in Korean Treated for Malignant Lymphoma

1608 A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

1609 Long-Term Outcome of Gemcitabine, Vinorelbine, Liposomal-Doxorubicin (GVD) As Salvage Regimen for Patients with Previously Heavily Treated Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma

1610 Prognostic Factors of Elderly Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Performance Status and Age Over Eighty, but Neither Lactate Dehydrogenase Level, Stage, Nor Relative Dose Intensity Delivered, Associated with Clinical Outcome

1611 Concurrent Radiotherapy and Dexamethasone, Etoposide, Ifosfamide, and Carboplatin (DeVIC) for Patients with Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Single Institution Analysis in Japan

1612 PET Evaluation Before Autografting Has a Strong Prognostic Impact in High-Risk, Relapsed Follicular Lymphoma Patients

1613 Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

1614 FDG-Positron Emission Tomography in T-Cell Lymphoma

1615 Retherapy with Bendamustine-Containing Regimens in Patients with Relapsed/Refractory CLL and Indolent Lymphomas Achieves High Response Rates

1616 Prospective Study to Evaluate the Efficacy and Safety of Gemcitabine Combined with GMCSF and Rituximab in Heavily Pre-Treated Relapsed / Refractory B-Lymphoproliferative Disorders

1617 Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues

1618 DA-EPOCH Chemotherapy Is Highly Effective in ALK-Positive and ALK-Negative ALCL: Results of a Prospective Study of PTCL Subtypes in Adults

1619 PET -CT Adapted Therapy After 3 Cycles of ABVD for All Stages of Hodgkin Lymphoma. Preliminary Results in 193 Patients

1620 Early and Permanent Telomere Shortening in Bone Marrow-Derived Cells Following Chemotherapy: A Parallel Study In Vivo in Lymphoma Patients and In Vitro in Cultured Mesenchymal Stem Cells

1621 Lenalidomide and Rituximab Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma Is Associated with Unacceptable Myelotoxicity

1622 The Evaluation of Clinical and Molecular Response to High-Dose Chemotherapy Protocol NHL BFM-90 in Adults with Anaplastic Large Cell ALK-Positive Lymphoma

1623 A Restrospective Review of Peripheral T-Cell Lymphoma in a Single Institution Between 2000 and 2010

1624 A Phase I Study of the Combination of Azacitidine, Cyclophosphamide, Vincristine, and Rituximab in Relapsed and Refractory Lymphoma

1625 Dose-Intensified CHOP with Rituximab (R-Double-CHOP) Followed by Consolidating High-Dose Chemotherapy Is An Effective Treatment for Younger Patients with Advanced Diffuse Large B-Cell Lymphoma

1626 R-CHOP21 Vs R-CHOP14 in Diffuse Large B-Cell Lymphoma Patients: Results From a Multicentre Retrospective Study

1627 Therapeutic Comparision of Surgical Resection Followed by R-CHOP and R-CHOP Alone for Primary Localized Intestinal Diffuse Large B Cell Lymphoma

1628 Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL)

1629 Rituxiamb Did Not Improve Clinical Outcomes In AIDS-Related Burkitt Lymphoma

1630 Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

1631 Rituximab Plus Dose Intense Rapid-Cycling Chemotherapy with Intrathecal CNS Prophylaxis in Patients with Burkitt Lymphoma (BL) and Intermediate Unclassifiable Diffuse Large B-Cell Lymphoma/BL: Single Institution Experience

1632 Phase I Study of Escalating Doses of Lenalidomide Combined with R-CHOP (R2-CHOP) for Front-Line Treatment of B-Cell Lymphomas

1633 Superior Immunogenicity of Idiotype Fab Fragments As Compared to Entire Immunoglobulin for Active Lymphoma Immunotherapy

1634 First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial

1635 Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma

1636 Phase 1 Study of TRU-016, An Anti-CD37 SMIP^TM Protein in Relapsed and/or Refractory NHL Patients

1637 Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

1638 Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL

1639 Prolonged Remission Duration with Interferon Maintenance After Rituximab-Containing Induction in First-Line Advanced Stage Lymphoplasmacytic Lymphoma – a Retrospective Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

1640 Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy

1641 Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab

1642 Phase I Study of mTOR Inhibitor Everolimus Plus CHOP in Patients with Advanced, Aggressive T-Cell lymphomas

1643 Treatment with a Bortezomib-Containing Regimen Is Associated with Better Therapeutic Outcomes in Patients with Waldenstrom’s Macroglobulinemia Who Have Familial Disease Predisposition

1644 Rituximab Cerebrospinal Fluid Levels in Patients with Primary Central Nervous System Lymphoma Treated with Intravenous High Dose Rituximab

1645 Lymphopenia and EBER-Negativity Predict Poor Survival in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD) Treated in the Rituximab Era

1646 A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL

1647 Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

1648 Phase I, Multicenter, Open Label, Dose Escalation of ⁹⁰yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B‑Cell Lymphoma

1649 Idiotypic Vaccination of Patients with Relapsed Follicular Lymphoma Using a Novel Vaccine Formulation Including a Tobacco Plant-Produced Tumor Specific Idiotype

1650 Synergistic Preclinical Activity of Bortezomib with Suberoylanilide Hydroxamic Acid (SAHA) in Primary Effusion Lymphoma (PEL)

1651 Antibody-Induced Non-Apoptotic Cell Death in Human Lymphoma and Leukemia Cells Is Mediated Through NADPH Oxidase-Derived Reactive Oxygen Species

1652 Contrary Functions of NF-κB Signaling in Anti-Cancer Treatment Outcome

1653 Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma

1654 PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients

1655 Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6

1656 Cyclin D1 Over-Expressing Mantle Cell Lymphoma Cells Are Hypersensitive to Inhibition of Fatty Acid Synthase (FASN)

1657 Manipulating Tumor Associated Macrophages (TAM) in a Mouse Model of B-Cell Non-Hodgkin Lymphoma (NHL)

1658 Improving T Cell Therapy for Relapsed EBV-Negative Hodgkin’s Lymphoma by Targeting Upregulated MAGE-A4

1659 New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas

1660 LFB-R603, a Third-Generation Monoclonal Anti-CD20 Antibody Displays An Additive Antitumor Activity with Antileukemic Chemotherapeutic Agents in Mouse Xenograft Models

1661 Src Family Tyrosine Kinases Are Involved in the Transcriptional Regulation of CD20 Levels

1662 Pro-Apoptotic Effect of An Anti-CD37 Scfv-Fc Fusion Protein, in Combination with the Anti-CD20 Antibody, Ofatumumab, on Tumor Cells From B-Cell Malignancies

1663 Pro-Apoptotic Activity of Honokiol Analogues in B-Cell Lymphoid Malignancies

1664 Differential Role of the B-Cell Receptor Pathway in Diffuse Large Cell B Cell Lymphoma: Temsirolimus Has Additive Effects in Combination with the BTK Inhibitor PCI-32765 and PI3K Inhibitor Cal101 but Antagonizes Bortezomib in GCB Subtype

1665 hsTRAIL/Apo2L Induces Apoptosis in Enteropathy-Associated T-Cell Lymphoma

1888 Evidence for the Involvement of CXCR4 Signaling in In Vivo Self-Renewal of Transplanted Hematopoietic Stem Cells

1889 Impairment of Hematopoietic Stem Cell (HSC) Niche by G-CSF Is Associated with Rapid Mobilization of Serially Reconstituting HSC and Reduced Competitive Repopulation of Mobilized Bone Marrow

1890 Tracking Reconstitution Dynamics in Mice Co-Transplanted with Hematopoietic Stem Cells From Nine Distinguishable Donor Types

1891 Peripheral Blood Stem Cell Mobilization with Single Agent Plerixafor Induces FoxP3 Expression in Donor T Cells and Enables Durable Long Term Hematopoietic Engraftment Across Mismatched Major Histocompatibility Complex Barriers

1892 Distinct Human Cell Populations Produce Rapidly Detectable Levels of Neutrophils and Platelets in NOD/SCID-IL-2Receptor Gamma Chain Null Mice Transgenically Engineered to Produce Human Myeloid Growth Factors

1893 Loss of Stem Cell Quiescence and Impaired Stem Cell Function of CD34⁺/CD38^low Cells One Year Following Autologous Stem Cell Transplantation

1894 Lack of CD34 Expression in Acute Myeloid Leukemia (AML) Is a Favorable Prognostic Factor in Patients Treated with Stem Cell Transplant Irrespective of the Cytogenetic Risk

1895 The Central Nervous System Is a Target Organ of Acute Graft-Versus-Host Disease

1896 Donor Immunization with WT1 Peptide Augments Anti-Leukemic Activity After MHC-Matched Bone Marrow Transplantation

1897 A Plasmin Inhibitor Prevents Lethal Acute Graft-Versus-Host Disease in Mice

1898 Effective Prevention of Acute Graft-Verses-Host Disease by Targeting PKC Alpha and PKC Theta in Mice

1899 Leukemia Escape From HLA-Specific T Lymphocyte Pressure in a Recipient of HLA One Locus-Mismatched Bone Marrow Transplantation

1900 The Inhibitory Receptor LAG-3 Is Not Essential for Regulatory T Cells Function but Influences Donor T Cell Potency in Acute Graft-Versus-Host-Disease

1901 Decitabine Can Increase the Induction of Regulatory γδ T Cells with Enhanced Immunosuppression on Graft-Versus-Host Disease From Adult Human Peripheral Blood Mononuclear Cells

1902 Prevention of Idiopathic Pneumonia Syndrome by Intra-Bone Marrow Injection of Donor Cells

1903 Janus Kinase-2 Inhibition Induces Durable Tolerance to Alloantigen by Dendritic Cell-Stimulated Human T Cells, Yet Preserves Immunity to Recall Antigen

1904 Acute Gvhd Induced by In Utero Hematopoietic Cell Transplantation Is Reversed by a Regulatory Response Resulting in a Potent Graft Vs. Hematopoietic Effect without Clinical Gvhd

1905 Thymic Dendritc Cells Generated Ex Vivo Induce Donor Regulatory T Cell Differentiation and Hasten Immune Reconstitution After Hematopoietic Stem Cell Transplantation

1906 Stat3 Activation in Donor CD4 T-Cells Is Critical for Acute Gvhd

1907 Human Mesenchymal Stem Cells Attenuate Graft-Versus-Host Disease and Maintain Graft-Versus-Leukemia in Murine Allogeneic Bone Marrow Transplantation

1908 Targeting Leukemias by CD123 Specific Chimeric Antigen Receptor

1935 Fludarabine-Based Reduced Intensity Hematopoietic Stem Cell Transplantation (RIST) for Patients Aged 50-70 Years with Acute Lymphoblastic Leukemia (ALL) in Remission: A Study From the ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

1936 Graft-Failure After Allogeneic Stem Cell Transplantation. Outcome and Prognostic Factors in 80 Patients

1937 Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism

1938 Allogeneic Hematopoietic Cell Transplantation with FLAMSA-RIC Can Overcome the Poor Prognosis of Primary Refractory or Relapsed AML

1939 Whole Blood Donor Chimerism At Day 30 After Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation Predicts Disease Relapse, and Is Strongly Associated with Pretransplant Lymphodepletion

1940 Beneficial Effect of Escalated Doses of Busulfan (BU) Delivered by Targeted Pharmacokinetics and Prolonged Continuous Infusion on Relapse Free and Overall Survival in Matched Related and Unrelated Allogeneic Transplant Patients with Hematologic Malignancies

1941 Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β-Thalassemia Major Undergoing Allogeneic HSCT

1942 T-Cell Depleted (TCD) Hematopoietic Stem Cell (HSC) Boosts From the Original Donor without Conditioning for Poor Graft Function (PGF) Following Allogeneic Hematopoietic Stem Cell Transplants (HSCT)

1943 Umbilical Cord Blood Transplantation in Patients with Hematological Malignancies Using a Non-ATG Containing Reduced Intensity Preparative Regimen

1944 Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens

1945 Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation

1946 G-CSF Affects the Distribution and Clonality of TRGV and TRDV Repertoire of T Cells and the Expression Pattern of CD3 Genes

1947 Use of Romiplostim to Facilitate Platelet Engraftment in Allogeneic Hematopoietic Transplantation

1948 Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study

1949 Allogeneic Hematopoietic Stem Cell Transplantation From HBsAg-Positive Donors Into HBsAg-Negative Recipients: A Safety and Practicable Regimen Under Active Prophylactic Anti-HBV Therapy

1950 Reduced-Intensity Stem Cell Transplantation Is a Promising Therapeutic Strategy for Pediatric Patients with Wiskott-Aldrich Syndrome: A Case Series of 7 Patients with a Uniform Reduced-Intensity Conditioning

1951 Incidence, Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation

1952 Allogeneic Stem Cell Transplantation From Matched Related Donor in Patients Over the Age of 55 Years: A Prospective Multicenter Phase II Study of a Reduced Intensity Conditioning Associating Fludarabin-IV Busulfan and Thymoglobulin

1953 Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) with FBA/FBAA Regimen Based Reduced-Intensity Conditioning: A Multicenter Clinical Trial in China

1954 Prospective Weekly Multiple Viral Monitoring in Blood Using Multiplex PCR Assay Early After Hematopoietic Stem Cell Transplantation

1955 Desensitization for Mismatched Hematopoietic Stem Cell Transplantation (HSCT)

1956 Retransplantation From Haploidentical Donors After Graft Failure in Pediatric Patients Results in Low Transplant Related Mortality and Favourable Long Term Survival

1957 Outcome of High-Risk and Refractory AML/MDS Patients Receiving a FLAMSA Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)

1958 Cytomegalovirus (CMV) gB3 Genotype Is Associated with Acute Gvhd and CMV Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients (HSCT)

1959 Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis

1960 Human Herpes Virus-6 and Clinical Manifestations After Allogeneic Hematopoietic Stem Cell Transplantation

1961 Clinical and Pharmacokinetic Evaluation of Prophylactic Micafungin 150mg Daily Against Invasive Fungal Infections in Cord Blood Transplant Recipients

1962An Interim Evaluation of Systemic F-Ara-a Exposure in Pediatric Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients Using An Optimal Sampling Design

1963 PCR Analysis of Bacteria and Fungi in Early Phase of Hematopoietic Stem Cell Transplantation

1964 Outcome of Busulfan and Fludarabine-Based Reduced Intensity Conditioning Regimen for Related and Unrelated HSCT in Fanconi Anemia Patients

1965 Myeloablative Conditioning with Pharmacokinetic-Targeted Intravenous Busulfan and Cyclophosphamide in Unrelated Cord Blood Transplantation for Myeloid Malignancies in Children

1966 Targeting Busulfan to Concentration Steady State of 600-700 ng/Ml Is Associated with Robust Engraftment and Decreased Toxicity in Patients with Sickle Cell Disease Receiving An HLA Identical Donor Transplant

1967 Cardiac QTc Interval Characteristics and Behavior in 995 Consecutive Hematopoietic Cell Transplantation Patients At a Single Institution

499 A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL)

500 Interim Restaging PET/CT-Guided High Dose Sequential Induction Therapy with Autologous Stem Cell Transplantation (ASCT) Does Not Improve Outcome for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials.Gov Identifier: NCT00530179

501 Conditioning Intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL)

502 The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party

503 Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Extranodal NK/T-Cell Lymphoma, Nasal Type: Analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group

504 Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) – a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)

583 Global Phosphoproteomic Analysis of B-Cell Lymphoma Signatures Reveals the Role of Active B-Cell Receptor Signaling in Germinal Center Derived NHLs

584 HGAL-a Germinal Center Specific Protein, Enhances B-Cell Receptor Signaling by Activation of Syk, Leading to Follicular Lymphoproliferation

High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma

586 NPM-ALK Regulated GSK3β Phosphorylation Results in Mcl-1 and CDC25A Accumulation and Enhanced Oncogenic Potential

587 The Hexosamine Biosyntheic Pathway and Platinum-Ethylenedicysteine-Glucosamine (Pt-ECG) for Targeted Therapy in Diffuse Large B-Cell Lymphoma

588 Metabolic Profiling of CNS Lymphoma and Its Microenvironment

589 Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results

590 Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6

591 Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

592 Improved Outcome of Elderly Poor-Prognosis DLBCL Patients with 6xCHOP-14 and 8 Applications of Rituximab (R) Given Over An Extended Period: Results of the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

593 Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

594 MYC⁺ Diffuse Large B Cell Lymphomas (DLBCL) Treated in Randomized Prospective Salvage Therapy, RICE or RDHAP Followed by BEAM Plus Autologous Stem Cell Transplantation (ASCT). A BioCORAL Report

595 Developing a Novel Class of Drug to Inhibit Protein Arginine Methyltransferase 5 (PRMT5) Enzyme Dysregulation in Mantle Cell Lymphoma

596 The Bruton Tyrosine Kinase Inhibitor, PCI-32765, Inhibits Activation and Proliferation of Human Chronic Lymphocytic Leukemia Cells in the NSG Xenograph Mouse Model of the Tissue Microenvironment

597 Disruption of MYD88 Pathway Signaling Leads to Loss of Constitutive IRAK1, NF-κβ and JAK/STAT Signaling and Induces Apoptosis of Cells Expressing the MYD88 L265P Mutation in Waldenstrom’s Macroglobulinemia

598 Development of a Novel Small Molecule CRM-1 Inhibitor for Non Hodgkin’s Lymphoma

599 Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL)

600 FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death

643Naïve CD4+ T Cells Modified to Express a ROR1-Specific CAR Mediate Anti-Tumor Activity and Provide Superior Help to CD8+ ROR1-CAR T Cells

644 Genetic Modification of Multi Leukemia Antigen-Specific Cytotoxic T Lymphocytes (CTL) to Enhance In Vivo Safety and Persistency

645 Redirected CD4⁺ T Cells Using WT1-Specific T-Cell Receptor Gene Transfer Can Supply Multifactorial Help to Enhance the Anti-Leukemia Reactivity Mediated by Similarly Redirected CD8⁺ T Cells Using the Identical Gene Transfer

646 CMV-Specific T-Cells Are More Effective Than WT-1-Specific T-Cells in Eradicating Clonogenic Tumor Cells Co-Expressing CMVpp65 and WT-1 in-Vivo and Both Types of T-Cells Are Functionally Augmented in the Presence of IL-15/IL-15Rα

647 Enrichment of Allogeneic Tumor Antigen-Specific T Cells From Bone Marrow (BM) of Patients Treated with High-Dose Post-Transplant Cyclophoshamide (Cy) – A Novel Approach to Adoptive Immunotherapy

648 HLA Class II Disparity Is Necessary and Sufficient for Induction of Effective Anti-Tumor Immunity by Donor Lymphocyte Infusion in a NOD/Scid Mouse Model for Human Acute Lymphoblastic Leukemia

649 HHV-6-Associated Post-Transplantation Acute Limbic Encephalitis Following Cord Blood Stem Cell Transplantation: A Cohort Analysis

650 Determining Late Engraftment Following Single Cord, Unrelated Transplantation: An Analysis of the Eurocord Registry

651 Possible Two Different Mechanisms of Engraftment Failure in Cord Blood Transplantation: Graft Rejection and Poor Graft Function

652 Influence of Infused Naïve CD3⁺CD8⁺ and CD3⁺CD56⁺ NKT-Cells on Single Unit Dominance After Double Cord Blood Transplantation

653 FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation

654 Co-Infusion of Allogeneic Cord Blood with Haploidentical CD34+ Cells Improved Transplant Outcome for Patients with Severe Aplastic Anemia Undergoing Cord Blood Transplantation

655 Secondary Malignancies After Allogeneic Stem-Cell Transplantation in the Era of Reduced-Intensity Conditioning; The Incidence Is Not Reduced

656 Phase II Study of Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) As First Salvage Therapy in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT): Final Results From the AZARELA-Trial (NCT-00795548)

657 A Phase II Study of Sequential Administration of DLI and Cytokine Induced Killer (CIK) Cells in Patients with Hematologic Malignancies Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation: Preliminary Results

658 Novel Therapy with Interferon-α in Combination with Donor Lymphocyte Infusion for High Risk Acute Leukemia Patients Who Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

659 Pre-Emptive Therapy with Modified Donor Lymphocyte Infusion Could Reduce Relapse and Improve Survival in Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation

660 Pre-Emptive Donor Lymphocyte Infusions (DLI) Lead to High Cure Rates in T-Cell Depleted Allogeneic Haemopoietic Stem Cell Transplants for MDS/AML

661 Randomized Phase III Trial of ¹³¹iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)

662 Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without ⁹⁰yttrium Ibritumomab Tiuxetan (⁹⁰YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

663 A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

664 Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

665 Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes

666 Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT)

769 Impact of Tumor Infiltrating T Cells in Patients with Follicular Lymphoma At Diagnosis

770 IL-21 in the Bone Marrow Microenvironment Contributes to IgM Secretion and Proliferation of Malignant Cells in Waldenstrom’s Macroglobulinemia

771 Role of IL-4 in Inducing Immunosuppressive Tumor Microenvironment in Follicular Lymphoma

772 Synthetic Oligonucleotide Aptamer (a revolutionary antibody?) for Lymphoma Diagnosis

773 Identification of Differentially Expressed miRNAs in Peripheral t-Cell Lymphomas

774 Targeting of TNFAIP3 (A20) Links MiR-125a and MiR-125b to Constitutive Activation of the NF-ΚB Pathway and Lymphomagenesis

775 Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL)

776 International Phase III Study of Chlorambucil Versus Fludarabine As Initial Therapy for Waldenstrom’s Macroglobulinemia and Related Disorders: Results in 414 Patients on Behalf of FCG CLL/ WM , GOELAMS, GELA , NCRI, ALLG

777 Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL)

778 Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin’s Lymphoma

779 A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

780 Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era

817 Over-Expression of TRAIL on Donor T Cells Enhances GVT and Suppresses Gvhd Via Elimination of Alloreactive T Cells and Host APC

818 In Vivo Assessment of T Effector, T Regulatory Cell, Dendritic Cell Interaction in Lymphoid Tissue Using Intravital Imaging During Acute GvHD

819 In Vivo Blockade of Individual Notch Ligands and Receptors Provides a New Targeted Therapeutic Approach In Graft-Versus-Host Disease

820 Inhibition of Histone Methylation Arrests Ongoing Graft-Versus-Host Diseases in Mice by Selectively Inducing Apoptosis of Alloreactive Effector T Cells

821 Induction of a Novel Population of CD8⁺ Foxp3⁺ Regulatory T Cells During Graft Versus Host Disease

822 Increased Susceptibility to Fungal Infection in Recipients with GVHD Is Not Due to Impaired Pathogen Clearance and Can Be Prevented by Co-Transfer of Donor CD4⁺CD25⁺ Regulatory T Cells

829 Indirect Evidence That Maternal Microchimerism in Cord Blood (CB) Mediates a Graft Versus Leukemia Effect After Transplantation to Unrelated CB Graft Recipients

830 Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies

831 Allogeneic Bone Marrow Transplantation From HLA Mismatched Family Donors in Children with Aplastic Anemia

832 Durable Chimerism, Absence of Graft-Versus-Host Disease and the Induction of Donor Specific Tolerance in Recipients of HLA Disparate Living Donor Kidney Transplants and Therapeutic Cell Transfer

833 T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide Results in Equivalent Non-Relapse Mortality and Disease-Free Survival Compared to Transplantation From HLA-Identical Sibling and Matched Unrelated Donors: A Stratified Cox Model Analysis of Two Hundred and Sixty Contemporaneous Allogeneic Transplants From a Single Center

834 Influence of Cytogenetic, Molecular Abnormalities and Other Risk Factors on the Outcomes of Children with Acute Myelogenous Leukemia Given An Unrelated Cord Blood Transplantation. A Survey on Behalf of Eurocord, ALWP and PDWP of EBMT

835 Is There an Impact of HLA Mismatch Direction on Outcomes After Umbilical Cord Blood Transplantantion?

836 Unrelated Cord Blood Transplantation Using Myeloablative Conditioning Regimen for Adults with Acute Myeloid Leukemia in First Complete Remission. A Survey by EUROCORD and the Acute Leukemia Working Party of the EBMT

837 A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children’s Oncology Group Study ASCT0431

838 Results of Allogeneic Hematopoietic Cell Transplantation in Persons with Fanconi Anemia and Pretransplant Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia

839 Long Term Follow-up of Haploidentical Hematopoietic Stem Cell Transplantation without in Vitro T Cell Depletion for the Treatment of Hematological Malignancies: 9-Year Experience of a Single Center

840 Significance of Missing Inhibitory KIR Ligands in Nonmyeloablative, HLA-Haploidentical (Haplo) BMT with Posttransplantation High-Dose Cyclophosphamide (PT/Cy)

3650 Single Nucleotide Polymorphisms (SNPs) in Genes for Glutathione-Related Metabolism, Cyclin D1, and DNA Repair As Predictive Biomarkers in Mantle Cell Lymphoma Patients Treated with R-HyperCVAD with Ten Year Clinical Follow-up

3651 SOX11 Expression Versus Indolent Clinical Course in Mantle Cell Lymphomas in a Population-Based Cohort From the Stockholm Region – SOX11 Negative Tumors Are Mostly p53 Positive, Contributing to Shorter Overall Survival

3652 Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma

3653 Overexpression of Metadherin in the Pathogenesis of Diffuse Large B-Cell Lymphoma

3654 Clinical and Biological Prognostic Factors Evaluation of Diffuse Large B-Cell Lymphoma Patients Relapsed or Refractory After Previous Line with Rituximab Plus Chemotherapy. Results of the Study PRO-R-IPI (NCT01369784)

3655 Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma: Results From a Phase II Study (BO20999)

3656 Involvement of the Syk-mTOR Pathway in Follicular Lymphoma Cell Invasion and Angiogenesis

3657 High Expression of the Endoplasmic Reticulum Protein MZB1 predicts Inferior Prognosis in Chronic Lymphocytic Leukemia, Follicular Lymphoma and Diffuse Large B-Cell Lymphoma and Is Associated with a Unique Gene Expression Profile

3658 Does 18F-Fluorodeoxyglucose Outperform 18F-Fluorothymidine When Using Positron Emission Tomography in Predicting Transformation of Indolent Non-Hodgkin’s Lymphoma

3659 Prognostic Value of C-Reactive Protein, Lactase Dehydrogenase and Anemia in Recurrent or Refractory Malignant Lymphoma

3660 Anaplastic Variant of Diffuse Large B-Cell Lymphoma: Re-Apprasial As Extra-Mediastinal Grey Zone Lymphoma Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma

3661 Symptoms and Toxicity of Rituximab Maintenance (R-M) Versus Observation (OBS) Following Rituximab Plus Chemotherapy in Patients with Follicular Lymphoma

3662 Molecular Diagnosis of Peripheral T-Cell Lymphoma/NOS From Formalin Fixed Paraffin Embedded Tissues

3663 MicroRNA Analysis in the Cerebrospinal Fluid and Blood Serum of Lymphoma Patients At Diagnosis and in Response to Therapy

3664 A Prognostic Nomogram for Diffuse Large B Cell Lymphoma Incorporating the International Prognostic Index with Interim-PET Findings

3665 The NF-κB-Inducing Kinase (NIK) Is Involved in Both Classical and Alternative NF-κB Activation and Is Necessary for the Survival of T Cell Lymphoma Cells

3666 Quantitative Analysis of AID Expression and Somatic Hypermutation Identifies Isotype-Switched and Non-Switched Follicular Lymphomas As Distinct Biological Subgroups

3667 Expression of Phospholipse C Gamma 2 in Diffuse Large B-Cell Lymphomas

3668 Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome

3669 MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia

3670 FDG-PET SUV Correlates with Expression of Genes Reflecting Proliferation, Metabolism, and Oncogene Activity in Mantle Cell Lymphoma (MCL)

3671 Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation

3672 M2 Macrophage Infiltration Is Closely Associated with Poor Prognosis for Adult T-Cell Leukemia/Lymphoma (ATLL)

3673 Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL

3674 Development and Validation of a Real Time Quantification Assay to Detect and Monitor BRAFV600E-Mutations in Hairy Cell Leukemia

3675 Late Onset Neutropenia Develops Selectively in Only a Subset of Patients with T Large Granular Lymphocyte Proliferation After Rituximab Treatment for Lymphoma

3676 Prognostic Role of Host Immune Gene Polymorphisms for Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in the GELA (Groupe d’Etude des Lymphomes de l’Adulte) Prospective Multicentric Program LNH2003

3677 Initial Features and Outcome Are Similar in Patients with Lymphoplasmacytic Lymphoma Regardless They Meet or Not Criteria of Waldenström Macroglobulinemia

3678 Silencing of SHP1 Is Frequent in Phospho-STAT3 Positive Diffuse Large Cell Lymphoma and This Silencing Is Independent of Methylation of Cpg Islands

3679 Response Assessment Using Early and End-of-Treatment 18F-FLT PET Can Predict Outcome in Patients with Non-Hodgkin Lymphoma

3680 Clues to the Pathogenesis of Waldenström Macroglobulinemia and Other Monoclonal IgM Disorders Provided by the Analysis of Immunoglobulin Heavy Chain Gene Rearrangement and Clustering of B-Cell Receptors

3681 Sarcopenia Determined by Computed Tomography (CT) imaging is a Better Prognosis Factor Than Albuminemia or Charlson Index in Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

3682 Meta-Analysis of Diffuse Large B-Cell Lymphoma Gene Expression Identifies Novel and Recurrent Biological Connections

3683 Dual Translocation Is An Independent Poor Prognostic Factor in Diffuse Large B-Cell Lymphoma

3684 A Variety of T-Cell Subsets Contribute to CD4+ T-Cell Infiltration in Diffuse Large B-Cell Lymphoma and Both Total CD4+ and CD4+FoxP3+ T-Cell Numbers Predict Clinical Outcome

3685 CD20, CD22, CD23, but Not CD37 Expression on CD19⁺ B-Cells Is Altered by Exogenous Factors in a Sub-Population of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL) Patients

3686 Prognostic Value of 18F-FDG Positron Emission Tomography Used for Assessment of the First Line Therapy in 410 Diffuse Large B-Cell Lymphoma Patients: A Daily Practice Evaluation Before and After the Prescription of This Metab

3687 Incremental Value in Outcome Prediction with Molecular Signatures in Diffuse Large B-Cell Lymphoma

3688 Activity of Bruton’s Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target

3689 Absence of Anaplastic Large Cell Lymphoma Cases in a Large Cohort of Danish Women with Breast Implants: Results of a Nationwide, Population-Based Study

3690 TLR-9 and B-Cell Antigen Receptor Triggering of Primary B Cells From Mantle Cell Lymphoma Induce Cell Proliferation and Telomerase Activity

3691 UCH-L1 Is a Novel Regulator of mTOR Signaling That May Predict a Poor Response to mTOR Inhibition in Patients with B-Cell Lymphoma

3692 Incidence of Peripheral Neuropathy in Waldenström Macroglobulinemia Patients At Diagnosis

3693 A Retrospective Analysis of All Hematological Malignancies in Patients Infected with HIV, a Subset Analysis of the CHAMP Study (Cook County Hospital (CCH) AIDS Malignancy Project)

3694 Inhibition of Caspase-8 Activity Caused by Overexpression of BCL10 Contributes to the Pathogenesis of High-Grade MALT Lymphoma

3695 DNA Microarray Analysis in DLBCL Dependent on Skp2 Expression

3696 Cross-Talk Between Tumor B Cells, Follicular Dendritic Cells, and Follicular Helper T Cells: Implications for Follicular Lymphoma Pathogenesis and Therapy

3697 Phase I Trial Evaluating the Safety and Biological Activity of Iboctadekin (rhIL-18) in Combination with Rituximab in Patients with CD20+ B Cell Non-Hodgkin’s Lymphoma

3698 Evaluation in the Context of Daily Practice of Follicular Lymphoma patients’ Outcome Before and After Approval of Rituximab in First Line Therapy in This Indication: Results of a Retrospective Analysis of 247 Unselected Patients with a 5-Year Median of Follow-up

3699 Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results

3700 Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study

3701 A Phase II Trial of Ofatumumab in Subjects with Waldenstrom’s Macroglobulinemia

3702 Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies

3703Yttrium-90-Ibritumomab Tiuxetan and BuCyE High-Dose Chemotherapy Compared with BuCyE Alone As Conditioning Regimen in Patients with B-Cell Non-Hodgkin Lymphoma: IPI Matched Case Control Study At a Single Center

3704 Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000)

3705 Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients

3706 Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma

3707 Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin’s Lymphoma

3708 Characteristics and Effectiveness of Rituximab (R) Maintenance Regimens Among US Patients Diagnosed with Follicular Lymphoma (FL) 2004-2007

3709 A Phase I Study with the Bispecific Anti-CD30 x Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma

3710 Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies

3711 Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

3712 Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin’s Lymphoma Receiving Radioimmunotherapy

3713 Efficacy of ⁹⁰yttrium-Ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma

3714 An Escalated Dose of Bortezomib Plus Second Line Chemotherapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

3715 An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma

3716 Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial

3717Comparative Assessment of Different Clinically Utilized CD20 Directed Antibodies in Chronic Lymphocytic Leukemia (CLL) Cells Reveals Divergent NK-Cell, Monocyte and Macrophage Properties

3718 Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

3719 First-Line Radio-Immunotherapy of Newly Diagnosed, Advanced Follicular Non-Hodgkin Lymphoma with ¹³¹I-Rituximab: The INITIAL Study

3720 Long Term Followup of Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL)

4012 Plasma Levels of Soluble Interleukin-7 Receptor Alpha (sIL-7Ra) and IL-7Ra Polymorphism After Allogeneic Stemcell Transplantation

4013 Emergence of Donor T Cells That Recognize Nonpolymorphic Antigens During Graft Versus Host Disease

4014 MEK Inhibitors Selectively Suppress Human T Cell Alloreactivity in a Memory Stage-Dependent Manner

4015 Cell Autonomous Role of TGFβ and IL-2 Receptor in the In Vivo Generation of CD4 and CD8 Inducible Regulatory T Cells During Graft-Versus-Host Disease

4016 Possible Reduced Immunogenicity of Chromatin Modifying Agents Expanded Cord Blood Grafts Is Likely Due to STAT3 Inhibition

4017 The Effect of KIRs Expression Profile in Donor/Recipient Pairs in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation

4018 CD26 Blockade by Humanized Monoclonal Antibody Leads to Prophylaxis and Treatment of Graft-Versus-Host Disease (GVHD) in Hu-PBL-NOG Model Mice

4019 APG101 - a Novel Inhibitor of CD95/CD95L Signaling Prevents Graft-Versus-Host Disease without Disabling T Cell Effector Function and Anti-Tumor Activity

4020 Identification of Leukemia Associated Antigens From ANKRD17 and CDK4 Using Mass Spectrometry Based Screening

4021 Donor B Cells in Transplants Augment Clonal Expansion and Persistence of Pathogenic Donor CD4⁺ T Cells in Autoimmune-Like Chronic Graft-Versus-Host Disease

4022 Impaired Donor T Cell Egress From Recipient Lymphoid Tissue Profoundly Diminishes Acute GvHD

4023 Prevention of Graft-Versus-Host Disease by HY-Specific Induced Tregs Through Activation-Dependent Manner

4024 Pretreatment with Anti-CD3 Monoclonal Antibody Depletes Recipient CCR7⁺ Dendritic Cells and Prevents Graft-Versus-Host Disease While Preserving GVL Effects

4025 A Novel Model of Pre-Emptive ECP Treatment Shows Significant Reduction of Gvhd-Related Mortality In Mice

4026 Absence of STAT1 Signaling in Host Hematopoietic Cells Leads to Enhanced Gvhd Induction and Involves Increased Expression of MHC Class II and Reduced PD-L1 Expression on Dendritic Cells

4027 IL-15 Administration Increases Graft Versus Leukemia Activity in Recipients of Haploidentical Hematopoietic Stem Cell Transplantation

4028 Frequency and Intensity of Antibody Responses to Antigens Encoded by KDM5D (SMCY) and Other H-Y Genes After Allogeneic Hematopoietic Cell Transplantation

4029 Post-Transplant Cyclophosphamide (PTC) Gvhd Prophylaxis: Kinetics of Proliferation of Donor T Cells Affects Susceptibility to PTC Administration

4030 Graft T Cells Retard Stem Cell Derived Lymphoid Organ Reconstitution and Immune Function After Allogeneic Transplantation

4062 What Predicts High Risk Acute Gvhd At Diagnosis?: Identification of Those At Highest Risk by a Novel Acute Gvhd Risk Score

4063 Low Levels of 25-Hydroxyvitamin D Prior to Allogeneic Transplantation Correlate with the Development of Chronic Graft-Versus-Host Disease

4064 The Increase of Peripheral Blood Monocytes After Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Chronic Graft-Versus-Host Disease and Late Mortality

4065 The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation

4066 Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes

4067 Biomolecular Characteristics of Specific Regulartory T Cells of Graft-Versus-Disease Based on T-Cell Receptor Analysis

4068 High Level Secretion of HLA-G5 Might Inhibit the Incidence of Gvhd

4069 Association Between MDSCs and Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

4070 Anti-CD25 Monoclonal Antibody for Graft-Versus-Host Disease Prophylaxis Following Unrelated Donor Peripheral Blood Stem Cell Transplantation

4071 Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study

4072 Acute GVHD in AML and MDS Patients Receiving Matched Related Donor (MRD) Reduced-Intensity Conditioning Allogeneic Hematopoietic Progenitor Cell Transplant (RIC-AHPCT) Correlates with Major Histocompatibility Complex Class I-Related Molecule A (MICA) Gene Polymorphisms

4073 A Single Nucleotide Polymorphism in the NLRP3 Gene Is Associated with Acute Graft-Versus-Host Disease After HLA-Matched Unrelated Bone Marrow Transplantation

4074 Assessing the Validity of the NIH Response Criteria for Chronic Graft-Versus-Host Disease (cGVHD): Consensus Measures Correlate with Clinical Outcomes

4075 Immune Reconstitution After Cord Blood Transplantation in Adults Depends on Activity of Thymic Epithelial Cells and Vascular Endothelial Elements

4076 Chronic Graft-Versus-Host Disease and Systemic Sclerosis: The Same Pathophysiology?

4077 Characterization of Chronic Graft-Versus-Host Disease and Duration of Immunosuppression After Cord Blood Transplantation

4078 CD28-Directed T Cell Costimulation Blockade with Abatacept to Prevent GvHD During High-Risk Unrelated HSCT: A First-in-Disease Feasibility Trial

4079 Low Blood Levels of Th17 Cells Are Seen in Patients with aGvHD and Associate with Rather Poor Survival Post HSCT

4080 A Recessive Gene Variant in TGFB1 in the Donor Influences the Acute Graft Versus Host Disease Development and Impacts in the Outcome After Allogeneic Stem Cell Transplantation (Allo-SCT)

4081 Dual Production of IL-2 and IFN-Gamma by CMV-Specific CD8+ T-Cells Is a Hallmark of Their Ability to Control CMV Reactivation in Patients After Hematopoietic Stem Cell Transplantation

4082 The Genotype in the Donor and Recipient for the Polymorphim -174 G/C of the IL-6 Influences the Outcome of HLA-Identical Related Stem Cell Transplantation

4083 Infusion of CD19-Directed and Multivirus Specific Cytotoxic T Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation for B Cell Malignancies

4084 Eosinophilia As a Biomarker Predicting the Occurrence of Chronic Graft Versus Host Disease

4085 Elevated Absolute Lymphocyte Counts Following Acute Graft Vs. Host Disease Treatment Is Associated with Therapeutic Responses and Lower Non-Relapse Mortality Following Umbilical Cord Blood Transplant

4086 Selective Targeting of B Cells with Mesenchymal Stromal Cells Treatment Is An Efficacious Strategy for Cutaneous Cgvhd

4087 Secondary Primary Malignancies in Patients with Multiple Myeloma Treated with High-Dose Chemotherapy and Autologous Blood Stem Cell Transplantation

4088 Correlation Between Severity of cGvHD and Transplant Outcome: A Retrospective Monocenter Study Based on NIH Classification

4090 Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Severe Alpastic Anemia After Cyclophosphamide Plus Antithymocyte Globulin Conditioning Regimen

4091 CD34 Expression in Adult Acute Lymphoblastic Leukemia (ALL) Is a Favorable Prognostic Factor in Patients Treated with Stem Cell Transplant in First Remission

4092 CD11b Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation

4093 Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies: Factors Impacting Its Occurrence and Treatment Options for a Better Management

4094 Upfront Tandem Autologous Stem Cell Transplant Is Superior to Autologous or Allogeneic Stem Cell Transplant After Failure of a 1st Autologous Transplant

4095 Nelarabine-Based Salvage Therapy in Adult Patients with T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (T-ALL/LL) Relapsing After Allogeneic Stem Cell Transplantation: A French Experience on Behalf of the Group for Research in Adult Lymphoblastic Leukemia (GRAAL

4096 Long-Term Survival and Quality of Life Assessment After Allogeneic Stem-Cell Transplantation; Comparable Results Following Myeloablative and Reduced-Intensity Conditioning

4097 High Throughput Screening for Antibody Responses Against H-Y Antigens and Their X-Variants in Allogeneic Hematopoeietic Stem Cell Transplantation

4098 CXCR4 allelic Variations Influence Hematological Recovery Following Autologous Stem Cell Transplantation

4099 Chronic Graft Versus Host Disease (GVHD) Does Not Impact Cardiovascular Risk Factors in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation (SCT) up to the Second Decade Post-Transplant

4100 Long-Term Complications (LTC) and Quality of Life (QOL) After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT)

4101 Outcome of Children Who Experience Disease Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies

4102 Monitoring of Wilms’ Tumor Gene 1 Levels Predict Early Relapse After Allogeneic Hematopoietic Stem Cells Transplantation in Patients with High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

4103 The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission

4104 Massively Parallel Immunoglobulin Gene Sequencing Provides Ultra-Sensitive Minimal Residual Disease Detection and Predicts Post-Transplant Relapse in Acute Lymphoblastic Leukemia by Three to Six Months

4105 Gonadal Function In Patients with Beta-Thalassemia Major Following Bone Marrow Transplantation

4106 Conditioning with Treosulfan and Fludarabine for Patients with Refractory or Relapsed Non-Hodgkin Lymphoma (NHL)

4107 Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Philadelphia Chromosome Acute Lymphoblastic Leukemia (Ph+ALL) in First Complete Remission (CR1) At the Era of Tyrosine Kinase Inhibitors (TKI): A Survey From the Acute Leukemia Working Party (ALWP) of EBMT

4108 A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma

4109 Impact of Prophylactic CD8-Depleted Donor-Lymphocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation and Alemtuzumab Mediated T-Cell Depletion

4110 First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant

4111 Very Good Partial Response and Complete Response Predict Superior Overall Survival and Progression Free Survival After Single Autologous Stem Cell Transplant in Patients with Multiple Myeloma

4112 Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin’s Lymphoma (NHL) Outcomes Database Project

4113 Reduced Intensity Conditioning Regimens Do Not Offer a Survival Advantage to Myeloma Patients Receiving Allogeneic Stem Cell Hematopoietic Transplantation : A Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC) Registry Study

4114 Unrelated Cord Blood Transplantation (UCBT) in Adult and Pediatric Acute Lymphoblastic Leukemia: Impact of Minimal Residual Disease on Relapse and Survival

4115 The Roel of High Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) In PATIENTS with POEMS SYNDROME: A Retrospective study of the MM Subcommittee of the Chronic Leukemia Working Party of the EBMT.

4116 Prognostic Significance of Detection of Minimal Residual Disease by Multiparametric Flow Cytometry Before Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

4117 Unmanipulated HLA-Haploidentical (2-3 antigen-mismatched) Stem Cell Transplantation Using Myeloablative or Reduced-Intensity Preconditioning Regimen

4118 Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience

4119 Response Before Autologous Hematopoietic Stem Cell Transplantation Is An Important Predictor of Outcome in Multiple Myeloma

4120 The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation

4121 Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre

4122 Prognostic Significance of Bone Marrow Involvement At Diagnosis and At the Time of Autologous Stem Cell Transplantation for Lymphoma Relapse

4123 Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion

4124 Comparison of Autologous and Allogeneic Transplantation As Therapy of First Relapse in Patients with Multiple Myeloma - Long-Term Follow up Analysis

4125 Allogeneic Stem Cell Transplantation Induces Long Term Survival in Pateitns with Advanced Chronic Myeloid Leukaemia:A Study of the British Society for Blood and Marrow Transplantation

4126 Early Hematopoietic Stem Cell Transplant Is Associated with Improved Outcomes in Children with MDS

4127 Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma

4128 Proteomic Pattern-Based Risk Stratification of Outcome Shows Significant Higher Accuracy Compared to HCT-CI in Patients with AML and MDS

4129 Potent Graft-Versus-Leukemia Effect After Reduced Intensity (RIC) Allogeneic Stem-Cell Transplantation (ASCT) As Post-Remission Therapy for Intermediate-Risk De-Novo Acute Myeloid Leukemia (AML) with FLT3-ITD Genotype or Wild-Type (WT) NPM1 and CEBPA without FLT3-ITD

4130 Therapy-Related Myelodysplastic Syndrome Following Treatment for Childhood Acute Lymphoblastic Leukemia: Outcome of Patients Registered in the EWOG-MDS 98/06 Studies

4132 Allogeneic Hematopoietic Peripheral Blood Stem-Cell Transplantation From HLA-Identical Siblings Versus Allelic-Matched Unrelated Donors (10/10 high resolution) in Patients with Acute Myeloid Leukemia and Myelodyplasic Syndrome After Reduced Intensity Conditioning

4133 Reduced Risk of Relapse In Pediatric ALL After Haploidentical Transplantation of T-Cell Depleted Grafts From KIR Haplotype B Donors

4134 RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma

4135 Increased Bone Marrow Plasma Cell Infiltration Pre-Transplant Is Associated with Worse Outcomes in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma

4136 Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-Versus-Host-Disease Upon Allogeneic Stem Cell Transplantation

4137 The Impact of Molecular Lesions in Post-Transplant Acute Myeloid Leukemia (AML) in Correlation with Cytogenetic Abnormalities

4138 12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years

4139 The Presence of An Internal Tandem Duplicate of FlT3 Receptor (ITD) Is An Unfavorable Prognostic Factor on the Outcome of Adult Patients with Acute Myeloid Leukemia (AML) Autografted in First Remission (CR1) Only in the Absence of An NPM1 Mutation

4140 Matched HLA Haplotype Contributes to Reduce Sever Acute GVHD with Conserving GVL Effect in HLA-Mismatched Cord Blood Transplantation

4141 NK Cell Activity Influences Long Term Outcome of Pediatric Leucemias After T Cell Depleted Stem Cell Transplantation

4142 A Randomized Clinical Trial of Lenalidomide and Dexamethasone with and without Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Interim Study Results

4143 A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998-2008

4144 Dyskeratosis Congenita: Evaluation of Immune Status and Hematopoietic Stem Cell Transplantation. A Literature and EBMT Data Base Survey of 75 Patients

4145 The Favorable Results of Allo-HSCT in TKI-Resistant CML

4146 Hematopoietic Cell Transplantation for FA Patients with Acute Leukemia or Advanced MDS

4147 Donor Choice for Allogeneic Stem Cell Transplantation for AML – A Retrospective Single Centre Long-Term Analysis

4148 The Impact of Bone Marrow Hematogones on Umbilical Cord Blood Transplant Outcomes in Acute Myeloid Leukemia Patients

4149 Therapy-Related Myelodysplasia/Acute Myeloid Leukemia (t-MDS/AML) After Conventionally-Treated Breast Cancer: Impact of Cytogenetics on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT)

4150 KIR-Ligand Incompatibility Is Not Associated with Relapse Reduction After Double Umbilical Cord Blood Transplantation

4151 Myeloablative Haploidentical Bone Marrow Transplantation with T Cell Replete Grafts and Post-Transplant Cyclophosphamide: Results of a Phase II Clinical Trial

4152 Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL)

4153 Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Patients ≥ 60 Years of Age with a Novel Reduced Intensity Conditioning Regimen Incorporating Extracorporeal Photopheresis

4154 Monosomal Karyotype in Myeloid Malignancies Is Prognostically Worse Even After Allogeneic Hematopoietc Stem Cell Transplantaion; Results From Two Transplant Centers

4155 Day 100 PET Scan Positivity Predicts for Worse Survival in Lymphoma Patients Given Allogeneic Peripheral Blood Stem Cells After Non-Myeloablative Conditioning

4156A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently

4157 A Pilot Phase II Study of C-MOPP-R, Ibritumomab Tiuxetan, and Autologous Transplant for Untreated and Relapsed Follicular Lymphoma: Response, Toxicity, and Feasibility

4158 A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma

4159 Mismatches in Ethnicity Between Donor and Recipient Affects Overall Survival In Umbilical Cord Blood Transplantation

4160 Non–myeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Low-Dose Total Body Irradiation and Peri-Transplant Rituximab for B Cell Non-Hodgkin Lymphoma: Favorable Disease Control in Chemosensitive Patients

4161 Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission

4162 Unrelated Donor Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Multiple Myeloma: The John Theurer Cancer Center Experience

4163 A Prospective Feasibility Trial of Unrelated Bone Marrow Transplantation with Reduced Intensity Conditioning Regimen for Elderly Patients with Adult T-Cell Leukemia/Lymphoma (ATL)

4164The Comparison of Allogeneic Stem Cell Transplantation From Family-Mismatched/Haploidentical Donors with Unrelated Donors in Adults with High-Risk Acute Myeloid Leukemia

4165 Comparable Outcome After Single-Antigen Mismatched Versus Matched Unrelated Donor Hematopoietic Cell Transplantation

4166 Clinical and Epidemiological Characteristics of Multiple Myeloma (MM): Comparison Between Hematopoietic Stem Cell Transplantation (HSCT) and Conventional Chemotherapy

4167 Graft Source and HLA-Matching Degree-Based Analyses of Long-Term Outcomes of Unrelated Donor Transplants in Adult High-Risk Acute Lymphoblastic Leukemia: Similar Outcomes Between Bone Marrow and Peripheral Blood Progenitor Cells Transplants

877 Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and At the End of Treatment with R-CHOP in High-Tumor Mass Follicular Lymphoma Patients : A GELA-GOELAMS Study

878 Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial

879 Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era

880 Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG

881 Characterization of Long-Term Survivors and a Predictive Model for Aggressive Adult T-Cell Leukemia-Lymphoma (ATL): An Ancillary Study by the Japan Clinical Oncology Group, JCOG0902A

882 Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL)

889 Haploidentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors Is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of A Prospective Phase II Trial

890 The Combination of Siromilus Plus Tacrolimus (SiTac) Improves the Results of Cyclosporine Plus Mycophenolate Mofetil (CsAMMF) After Reduced Intensity Conditioning (RIC) Unrelated Donor Allogeneic Transplantation.

891 Fludarabine and Targeted Busulfan Is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission.

892 Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS ; Results of a Randomized Phase III Study

893 Low Incidence of Severe Mucositis After Myeloablative, HLA-Matched Bone Marrow Transplantation and High Dose, Post-Transplantation Cyclophosphamide

894 Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd

949 The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study

950 Cell of Origin Determination in Diffuse Large B-Cell Lymphoma: Performance of Immunohistochemical (IHC) Algorithms and Ability to Predict Outcome

951 Exploring the Immune Microenvironment of Diffuse Large B Cell Lymphoma in a Tissue Microarray: Predicting Survival with a Score That Incorporates Macrophages, Cytotoxic and Regulatory T Cells

952 CXCR4 Antagonist BKT140 Synergizes with Rituximab, Targeting Non Hodgkin Lymphoma (NHL) In Vitro and In Vivo in a Xenograft Model with Bone Marrow Involvement

953 Detection and Characterization of Antigen-Driven CD8⁺ T Lymphocytes Specific for Wilms’ Tumor Antigen in Patients with Non-Hodgkin Lymphoma

954 Egress of CD19⁺CD5⁺ Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor, PCI-32765, in Mantle Cell Lymphoma Patients

955 Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma

956 Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins

957 A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

958 Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori-Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

959 Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma

960 Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation

1015 Reduced Intensity or Non-Ablative Hematopoietic Cell Transplantation in Older Patients with Non-Hodgkin Lymphoma (NHL): Encouraging Survival for Patients ≥55 Years

1016 Global Use and Trends in Hematopoietic Stem Cell Transplantation Analyzed by the Worldwide Network of Blood and Marrow Transplantation WBMT: A Targeted Approach for a Widening Gap

1017 Improved Clinical Outcomes of High Risk β Thalassemia Major Patients Under Going a HLA Matched Related Allogeneic Stem Cell Transplant with the Use of a Treosulphan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts

1018 Measurement of Liver Iron Concentration by Quantum Interference Device Biosusceptometry (SQUID) Validates Serum Ferritin As Prognostic Parameter for Allogeneic Stem Cell Transplantation

1019 Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

1020 Effect of Race on Outcomes After Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia

Table of contents

Clinical Allogeneic and Autologous Transplantation - Results: Allogeneic Hematopoietic Stem Cell Transplantation (conditioning regimen)